

The Royal Marsden NHS Foundation Trust
Drug & Therapeutic Committee minutes
24rd September 2019

Present: Consultant Breast and AOS (deputy chair)
Deputy Chief Pharmacist (acting)/Drug Resource Manager (secretary)
Consultant AOS
Consultant GI
Consultant Pharmacist
Consultant Palliative Care Unit
Consultant Paediatric Oncology Drug Development & Neuro-Oncology
Medicines Information and Palliative care Pharmacist

In attendance:

1. Minutes of the July meeting

a. Minutes – approved.

2. Conflict of Interest

No conflicts raised.

3. NICE Guidance update

1. TA591 Letemovir for preventing CMV after stem cell transplantation
2. TA589 Blinatumumab for treating ALL in remission with residual disease activity
3. TA598 Olaparib for maintenance treatment of BRCA mutation +ve ovarian, fallopian & peritoneal ca.
4. TA595 Dacomitinib for untreated EGFR +ve NSCLC
5. TA593 Ribociclib plus fulvestrant in HER2+ve advanced Breast ca.
6. TA592 Cemiplimab in metastatic or locally advanced cutaneous squamous cell ca.
7. TA600 Pembrolizumab plus carboplatin & paclitaxel for untreated met. Squam. NSCLC (+ve)

Relevant clinical leads made aware of the guidance.

4. One off drug use requests

1. Olaparib in BRCA2 mutated pancreatic cancer
2. Regorafenib & nivolumab in metastatic CRC
3. Atezolizumab plus carboplatin & etoposide in lung ca.
4. Nab-paclitaxel in HER2-ve gastric adenocarcinoma
5. Cefiderol in acinetobacter Baumanns complex due to resistance
6. Cabozantinib in medullary RCC
7. Ceritinib (via compassionate) in inflammatory myofibroblastic
8. Dabrafenib & trametinib in anaplastic thyroid ca.
9. Venetoclax & CPX-351 in refractory AML
10. Venetoclax in ALL
11. Venetoclax in combination with cytarabine in refractory AML
12. Osimertinib in locally advanced NSCLC

13. ECarboF in cisplatin resistant prostate ca.
 14. Olaparib in advanced BRCA2 germ line related Breast ca.
 15. Ibrutinib in multiple relapse CNS Lymphoma
 16. Pembrolizumab plus axitinib in mRCC
 17. Everolimus & vandetanib in DIPG (Diffuse intrinsic pontine glioma)
 18. Trifluridine-tipiracil plus bevacizumab in metastatic rectal ca. with KRAS mutation.
- All requests approved.

5. Atezolizumab in combination with carboplatin & etoposide. Presented by Lung unit

Proposed for use as 1st line treatment of extensive stage small cell lung cancer in combination with chemotherapy in line with NHSE approved Early Access Medicines Scheme.

Action:

Approved.

6. Phenzopyridine for radiation cystitis. Presented by Renal Unit

Proposed for use as symptomatic treatment for radiation cystitis for patients who are not having adequate symptoms' control with traditional analgesics or have a contra-indication for using NSAIDS or alternatively as a second option of short-term treatment for mild to moderate radiation cystitis.

Action:

Approved.

7. Immunotherapy Checkpoint Inhibitor Toxicity management algorithms (updates). Presented by the Acute oncology Service.

Action:

Approved.

8. IV iron guidelines. Presented by Anaesthetics.

Two guidelines developed one for Oncology setting & one for Surgery setting.

Action:

Approved.

9. Gene therapy/oncolytic viruses – prescribing requirements. Presented by Surgical unit

Proposal for the prescribing to be extended outside of medical oncologists. This request was made in view of the Skin Unit developing a business plan for surgeons and dermatologists to deliver talimogene laherparepvec (T-VEC), as this practice would currently not meet with the trusts SACT (including chemotherapy) guideline.

Action:

Approved, trust SACT guideline to be amended to include.

10. PGD: Chlorphenamine. Presented by Radiography.

Action:

Approved.

11. Parenteral Nutrition (PN) policy & prescription update. Presented by Dietetics & Pharmacy.

Update to policy.

Action:

Approved.

12. AOB

Date of the Next Meeting:

Tuesday 29th of October (pm), 15:00 – 17:00

Minutes Approved	DTC chair: Tuesday 26 th November 2019
------------------	---

Date of next meeting 29 th October 2019.
